Oncopharmacology Unit, Centre Antoine Lacassagne, 06189 Nice Cedex 2, France.
Pharmacogenomics. 2009 Aug;10(8):1277-83. doi: 10.2217/pgs.09.54.
Elevated tumoral vascular endothelial growth factor A (VEGF-A) expression is linked to poor survival in head and neck cancer patients. The aim of the present study was to analyze the influence of VEGF-A gene polymorphisms on tumoral VEGF-A expression and to test their prognostic value in head and neck cancer patients.
MATERIALS & METHODS: VEGF-A polymorphisms at position -2578C>A, -1498T>C, -1154G>A, -634G>C and 936C>T were analyzed (PCR-RFLP) in tumoral DNA, along with tumoral VEGF-A expression (ELISA), in 49 Caucasian head and neck cancer patients.
A trend towards a difference in tumoral VEGF-A expression depending on 936C>T polymorphism was observed, with a median at 540 pg/mg prot in CT + TT patients (n = 5) versus 940 pg/mg prot in CC patients (n = 44) (p = 0.064). VEGF-A expression was not related to any other polymorphism. Unlike tumoral VEGF-A expression, the analyzed genotypes were not related to patient survival.
As opposed to tumoral VEGF-A expression, VEGF-A gene polymorphisms are not of prognostic value in head and neck cancer patients. Further studies aimed at confirming the influence of VEGF-A 936C>T germinal polymorphism on tumoral VEGF-A expression are needed.
肿瘤血管内皮生长因子 A(VEGF-A)表达升高与头颈部癌症患者的预后不良有关。本研究旨在分析 VEGF-A 基因多态性对肿瘤 VEGF-A 表达的影响,并检验其对头颈部癌症患者的预后价值。
在 49 例白种人头颈部癌症患者的肿瘤 DNA 中,通过聚合酶链反应-限制性片段长度多态性(PCR-RFLP)分析 VEGF-A 位置-2578C>A、-1498T>C、-1154G>A、-634G>C 和 936C>T 的多态性,并通过酶联免疫吸附试验(ELISA)检测肿瘤 VEGF-A 表达。
观察到 936C>T 多态性与肿瘤 VEGF-A 表达之间存在差异的趋势,CT+TT 患者(n=5)的中位数为 540pg/mg prot,而 CC 患者(n=44)的中位数为 940pg/mg prot(p=0.064)。VEGF-A 表达与其他任何多态性无关。与肿瘤 VEGF-A 表达不同,分析的基因型与患者生存无关。
与肿瘤 VEGF-A 表达相反,VEGF-A 基因多态性对头颈部癌症患者的预后无价值。需要进一步的研究来证实 VEGF-A 936C>T 胚系多态性对肿瘤 VEGF-A 表达的影响。